This inventor holds 2 USPTO granted patents. Top assignee: Fibrogen, Inc.. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: Mark D Sternlicht: Innovator in Antisense Oligonucleotides
Introduction
Mark D Sternlicht is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. With a total of 2 patents, his work focuses on innovative solutions for medical conditions influenced by connective tissue growth factor (CTGF) expression.
Latest Patents
Sternlicht's latest patents include groundbreaking inventions related to connective tissue growth factor antisense oligonucleotides. These inventions target human CTGF mRNA and inhibit its expression. The patents disclose regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition. Furthermore, pharmaceutical compositions comprising these antisense oligonucleotides are also detailed, highlighting their potential use in treating disorders associated with CTGF expression.
Career Highlights
Mark D Sternlicht is currently associated with Fibrogen, Inc., where he continues to advance his research and innovations. His work has garnered attention in the scientific community for its potential impact on therapeutic applications.
Collaborations
Sternlicht collaborates with Todd W Seeley, contributing to the advancement of their shared research interests in biotechnology.
Conclusion
Mark D Sternlicht's contributions to the field of antisense oligonucleotides represent a significant advancement in medical research. His innovative work continues to pave the way for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile